Cara Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-07-02
- Employees
- 55
- Market Cap
- $19.6M
- Introduction
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
- Conditions
- Cholestatic Pruritus
- Interventions
- Drug: CR845 1.0 mgDrug: Placebo
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT03995212
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Morgantown, West Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Boston, Massachusetts, United States
Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects
- Conditions
- HealthyHemodialysis
- Interventions
- Drug: [14C] CR845
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03947970
- Locations
- 🇺🇸
Cara Therapeutics Study Site, San Antonio, Texas, United States
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Conditions
- Uremic Pruritus
- Interventions
- Drug: PlaceboDrug: CR845 0.5 mcg/kg
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 473
- Registration Number
- NCT03636269
- Locations
- 🇬🇧
Cara Therapeutics Study Site, Westcliff-on-Sea, United Kingdom
🇨🇳Cara Therapeutics Study Site 2, Taipei, Taiwan
🇰🇷Cara Therapeutics Study Site 3, Seoul, Korea, Republic of
A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus
- Conditions
- Chronic Kidney DiseasesPruritus
- Interventions
- Drug: Placebo Oral TabletDrug: CR845 0.25 mg Oral TabletDrug: CR845 0.5 mg Oral TabletDrug: CR845 1 mg Oral Tablet
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 269
- Registration Number
- NCT03617536
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Alexandria, Virginia, United States
🇺🇸Cara Therapeutics Study Site 2, Flint, Michigan, United States
🇺🇸Cara Therapeutics Study Site 1, Miami, Florida, United States
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
- Conditions
- Uremic Pruritus
- Interventions
- Drug: PlaceboDrug: CR845 0.5 mcg/kg
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 378
- Registration Number
- NCT03422653
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Wauwatosa, Wisconsin, United States
🇺🇸Cara Therapeutics Study Site 2, Beverly Hills, California, United States
🇺🇸Cara Therapeutics, La Mesa, California, United States
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 288
- Registration Number
- NCT03281538
- Locations
- 🇵🇷
Cara Therapeutics Study Site, San Juan, Puerto Rico
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
- Conditions
- Osteoarthritis, HipOsteoarthritis, KneeArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases
- Interventions
- Drug: CR845 tablet 1 mgDrug: CR845 tablet 2.5 mgDrug: CR845 tablet 5 mgDrug: Placebo tablet
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 761
- Registration Number
- NCT02944448
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Charlottesville, Virginia, United States
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Conditions
- Uremic Pruritus
- Interventions
- Drug: CR845 1 mcg/kgDrug: PlaceboDrug: CR845 0.5 mcg/kgDrug: CR845 1.5mcg/kg
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2020-07-29
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 226
- Registration Number
- NCT02858726
- Locations
- 🇺🇸
Cara Therapeutics Investigator Site, Philadelphia, Pennsylvania, United States
🇺🇸Cara Therapeutics Study Site, Milwaukee, Wisconsin, United States
🇺🇸Cara Therapetics Study Site, Knoxville, Tennessee, United States
A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
- Conditions
- Post Abdominal Surgery Pain
- Interventions
- Drug: CR845 IV 1 mcg/kgDrug: CR845 IV 0.5 mcg/kgDrug: Placebo IV
- First Posted Date
- 2015-09-07
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 451
- Registration Number
- NCT02542384
- Locations
- 🇺🇸
Cara Therapeutics Study Site, Salt Lake City, Utah, United States
A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
- Conditions
- Osteoarthritis
- Interventions
- Drug: CR845 5 mgDrug: CR845 0.25 mgDrug: CR845 0.50 mgDrug: CR845 1 mg
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2017-01-31
- Lead Sponsor
- Cara Therapeutics, Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT02524197
- Locations
- 🇺🇸
Heartland Clinical Research, Omaha, Nebraska, United States
🇺🇸Matthew Barton, MD, Las Vegas, Nevada, United States
🇺🇸Triad Clinical Trials, LLC, Greensboro, North Carolina, United States